CELL LINES
Contributor Information
- Name Anne-Marie Mes-Masson and Diane Provencher
- Institute Centre Hospitalier de Luniversité de Montréal
- Primary citation Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248
Tool Details
- Tool name: TOV-1369TR cell line
- Alternate names: TOV-1369TR
- Tool type: Cell Lines
- Organism: Human
- Donor: Grade 3 Stage IIIC; Mutations: TP53 Exon 7; Post-treatment for breast cancer 2 years before
- Tissue: Derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
- Gender: Female
- Cancer type: Gynaecologic cancer
- Morphology: Expresssion of tumor suppressor p53 present. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: no
- Growth properties: Adherent
- CRISPR: No
- Receptors of note: No
- Description: Epithelial ovarian cancer cell lines spontaneously derived from solid tumor at specific time points at diagnosis and relapse. Post-treatment for breast cancer 2 years before
- Research area: Cancer
- Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
- Additional notes: Patient was diagnosed with breast cancer 18 months before ovarian cancer diagnosis. After surgical resection for breast cancer and 14 months before ovarian cancer diagnosis, patient had docetaxel treatment. Patient was also entrolled in a clinical trial obtaining doxorubicin, docetaxel with or without cyclophosphamide and received radiotherapy 12 months before ovarian cancer diagnosis. After ovarian cancer diagnosis, patient received paclitaxel and carboplatin for 5 months and was initially responsive to treatment. However, due to carboplatin toxicity, she was treated with paclitaxel alone. This was discontinued after two cycles and patient had a relapse 7 months after cancer diagnosis. Patient then received 11 cycles of doxorubicin and topotecan was the final treatment given from 18-28 months. Patient later passed due to disease progression
- For Research Use Only
Target Details
Application Details
Handling
- Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
- Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
- Cultured in antibiotics?: Amphotericin B and Gentamicin
Documentation
Related Tools
References
- • Tomas et al. 2023. J Ovarian Res. 11
- • 16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11
- • 12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11
- • 12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4
- • 12:856424. PMID: 35600398
.svg)
.svg)
